GRO Biosciences has obtained an additional $60.3M in funding that the protein therapeutics-focused biotech will use to push its lead #gout treatment, ProGly-Uricase, into a #Phase1 trial of patients with elevated uric acid levels. It also has plans to use its tech to treat #autoimmunediseases without broadly suppressing the immune system. Horizon Therapeutics’ Krystexxa remains the only approved biologic to treat uncontrolled gout.
Conquest Research
Research Services
Winter Park, Florida 1,063 followers
Conquering Tomorrow’s Health Issues With Today’s Research
About us
Conquest Research was formed to offer the most efficient clinical research services to partners and pharmaceutical companies worldwide. With a leader who’s extremely passionate about advancing the clinical trial process through technology, our mission is to deliver high quality clinical research in a cost-effective and timely manner. Conquest Research offers services not only directly to pharmaceutical companies, but also to physician practices interested in conducting clinical trials to offer new and innovative treatment options to their patients.
- Website
-
http://www.conquestresearch.com
External link for Conquest Research
- Industry
- Research Services
- Company size
- 51-200 employees
- Headquarters
- Winter Park, Florida
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
2233 Lee Rd
Suite 101
Winter Park, Florida 32789, US
Employees at Conquest Research
-
Daniel Stoner, CPA
Chief Financial Officer at Conquest Research
-
Anand Patel
Chief Medical Officer at Conquest Research, Certified Principal Investigator, Interventional Pain Physician
-
Malisa Agard MD
Principal Investigator at Conquest Research Internal Medicine Physician
-
Chloe Eckel, MRA
Director of Business Operations at Conquest Research
Updates
-
Viking Therapeutics, Inc. will accelerate the development of its investigational subcutaneous GLP-1/GIP receptor dual agonist VK2735 for #obesity, with an eye towards starting #Phase3 development in the coming months. This follows promising findings from the Phase II VENTURE study, touting 9.1% #weightloss at the 2.5-mg dose level. Patients who were given the 15-mg dose saw a 14.7% drop in body weight. Compared with placebo, which cut weight by only 1.7%, the treatment effect of both doses was statistically significant.
Viking's obesity med set to charge into phase 3, with $300M earmarked for clinical program
fiercebiotech.com
-
Join #conquestresearch and Great Transitions today at 10:00 a.m. at the Winter Park Chamber of Commerce. Dr. Patel from Conquest Research and other expert panelists will cover vital topics and resources on living with #dementia and #AlzheimersDisease. Register at gtflorida.com or call 407-473-1153. #seniors #community #caregivers #Alzheimers #endalz
Great Transitions | Certified Senior Housing Realtors | Winter Park
gtflorida.com
-
Foralumab, an investigational #nasalspray being developed by Tiziana Life Sciences, has been cleared by the FDA for expanded use to treat moderate #AlzheimersDisease. Dosing of the first patient is expected to happen this month. Foralumab is an antibody designed to block CD3 proteins. Tiziana is also testing foralumab currently in a #Phase2 study for adults with nonactive secondary progressive #multiplesclerosis. #neurodegenerativediseases #ms #alzheimers #endalz
Alzheimer's therapy foralumab nasal spray cleared by FDA for...
https://alzheimersnewstoday.com
-
Phathom Pharmaceuticals has received #FDAapproval for Voquezna (vonoprazan) to relieve #heartburn related to non-erosive gastroesophageal reflux disease (GERD) in adults and is already approved for treating all severities of erosive #GERD, and in combination with antibiotics to treat H. pylori infection. Voquezna is a novel class of medicines that inhibit stomach acid secretion. The approval is supported by the positive results from the PHALCON-NERD-301 study. Phathom licensed the U.S. rights from Takeda.
Phathom Pharmaceuticals receives FDA approval for Voquezna to treat non-erosive GERD
outsourcing-pharma.com
-
Boehringer Ingelheim has partnered with Gubra, a specialized pre-clinical contract research services provider, to launch #Phase1 #clinicaltrials for BI 3034701. It is a novel long-acting peptide triple agonist with the potential to advance #obesity treatment as a next-generation, first-in-class therapy. The trial marks the first time administration of BI 3034701 to humans. It will enroll around 124 participants and the study is projected for completion in the latter half of 2025. #weightloss #weightmanagement
Boehringer, Gubra to start Phase 1 study of BI 3034701 obesity drug
worldpharmaceuticals.net
-
The Foundation for the National Institutes of Health (FNIH) announces #research effort to speed #Parkinsons diagnosis and enable earlier intervention. The Accelerating Medicines Partnership® in Parkinson’s Disease and Related Disorders (AMP® PDRD), managed by the FNIH, brings together the resources and expertise of its public sector partners such as the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA) at the The National Institutes of Health and the FDA. Private sector partners include The Michael J. Fox Foundation for Parkinson's Research, Sanofi, GSK, Denali Therapeutics, CurePSP, C2N Diagnostics and Aligning Science Across Parkinson’s | ASAP. The $21M commitment aims to identify unique #biomarkers that distinguish #ParkinsonsDisease from other conditions with similar pathologies to help decrease a risk for misdiagnosis that could undermine #clinicaltrials. #collaboration #partnership
GSK, Sanofi, Denali take part in FNIH Parkinson’s biomarker project
fiercebiotech.com
-
Asceneuron SA has secured funding to help progress its lead asset to treat #AlzheimersDisease. Its lead candidate, ASN51, is an oral small molecule designed to inhibit OGA, an enzyme associated with protein aggregation. The drug aims to prevent the aggregation of tau proteins and slow the progression of #Alzheimers. The funding will be used to push ASN51, which has so far completed five Phase I #clinicaltrials, into #Phase2 development, which will start later this year. #endalz
Novo Holdings Leads $100M Raise for Asceneuron’s Alzheimer’s Push
biospace.com
-
Silo Pharma Inc., focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, has entered into an exclusive global license agreement to further develop, manufacture, and commercialize its #Alzheimers drug SPC-14. It is a novel therapeutic that targets glutamate receptor NDMAR and serotonin type 4 receptor 5HT4 to treat cognitive and neuropsychiatric symptoms in #AlzheimersDisease. Early pre-clinical studies have shown stress reduction and cognitive improvement. Silo recently announced a similar exclusive license agreement for its lead drug candidate, SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
Silo Pharma Enters Exclusive Global License Agreement to Further Develop SPC-14
contractpharma.com
-
Join #conquestresearch and Great Transitions for an upcoming #seminar on Wed., July 24 at 10:00 a.m. at the Winter Park Chamber of Commerce. In the first seminar of the “Mind, Heart & Emotions” series, Dr. Patel from Conquest Research and other expert panelists will cover vital topics and resources on living with #dementia and #AlzheimersDisease. Register at gtflorida.com or call 407-473-1153. #seniors #community #caregivers #Alzheimers #endalz
Great Transitions | Certified Senior Housing Realtors | Winter Park
gtflorida.com